NI-3201
/ Light Chain Biosci
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
March 04, 2025
NI-3201 Is a Bispecific Antibody Mediating PD-L1-Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control.
(PubMed, Cancer Immunol Res)
- "Quantitative systems pharmacology modeling predicted that NI-3201 exposure results in antitumor activity in patients, but this remains to be investigated. Overall, this study suggests that by combining PD-L1 blockade with safe and effective CD28 co-stimulation, NI-3201 has the potential to improve cancer immunotherapy outcomes, and the clinical development of NI-3201 for PD-L1+ solid tumors is planned."
Journal • Cytomegalovirus Infection • Oncology • Solid Tumor • PD-L1
March 06, 2024
Preclinical development of NI-3201, a PD-L1xCD28 bispecific antibody mediating CD28 costimulation upon PD-L1 blockade
(AACR 2024)
- "The favorable profile seen in NHP was supported by data generated in vitro further de-risking the cytokine release syndrome (CRS) potential. Quantitative systems pharmacology (QSP) modelling integrating both in vitro and NHP data predicted a drug concentration required for optimal NI-3201 activity in the TME, and preliminary data suggests optimal patient activity at Q2W-Q3W dosing schedule.The anti-tumor activity as a single agent or as universal combination partner for TCEs, shown in vitro and in vivo, together with the favorable safety profile of NI-3201, support its clinical development planned to start in Q1 2025."
Preclinical • Colon Cancer • Colorectal Adenocarcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor • CRP • IL6
March 14, 2023
NI-3201,a PD-L1xCD28 bispecific antibody for immune checkpoint-dependent CD28 co-stimulation
(AACR 2023)
- "In immunocompetent huCD28-transgenic mice engrafted with huPD-L1-expressing murine colon adenocarcinoma MC38 cells, NI-3201 displayed superior single-agent activity as compared to the anti-PD-L1 antibody Atezolizumab, with tumor regression being observed in all treated mice. The mechanism of action of NI-3201 and the data presented herein support the use of this molecule as a universal combination partner for CD3-bispecifics. Pre-clinical development of NI-3201 is ongoing, with pharmacokinetic and tolerability studies in non-human primates planned for early 2023."
Colon Cancer • Colorectal Adenocarcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor • CD4 • CD8
1 to 3
Of
3
Go to page
1